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We have shown previously that truncation of the human ,3-globin pre-mRNA in the second exon, 14
nucleotides downstream from the 3' splice site, leads to inhibition of splicing but not cleavage at the 5' splice
site. We now show that several nonglobin sequences substituted at this site can restore splicing and that the
efficiency of splicing depends on the length of the second (downstream) exon and not a specific sequence.
Deletions in the first exon have no effect on the efficiency of in vitro splicing. Surprisingly, an intron fragment
from the 5' region of the human or rabbit j3-globin intron 2, when placed 14 nucleotides downstream from the
3' splice site, inhibited all the steps in splicing beginning with cleavage at the 5' splice site. This result suggests
that the intron 2 fragment carries a "poison" sequence that can inhibit the splicing of an upstream intron.
All pre-mRNAs that contain introns have a number of
specific sequence elements that are essential for accurate
and efficient splicing. These elements appear to be contained
within the intron and include the 5' and 3' splice sites, the
branch point near the 3' splice site, and the polypyrimidine
region. The importance of these sequences has been shown
by (i) their high degree of sequence conservation between
pre-mRNAs (18), (ii) the occurrence of mutations in each of
the elements which severely alter or completely inactivate
normal splicing (for recent reviews see references 9, 21, and
27), and (iii) the observation that these sequences specifi-
cally bind ribonucleoprotein particles (RNPs) shown to be
involved in pre-mRNA splicing (reviewed in reference 16).
It is likely that there are additional sequence elements in
pre-mRNA involved in the regulation of splicing that have
not yet been characterized. We have shown previously that
efficient removal of intron 1 of the human ,B-globin pre-
mRNA can be dramatically reduced in vitro by truncating
the transcript so that only 14 nucleotides of the second exon
remain. This transcript is able to undergo the first step in
splicing, i.e., cleavage at the 5' splice site and lariat forma-
tion, but is unable to efficiently generate the final spliced
product or the released lariat intron (7). Similar observations
have also been reported by Ruskin and Green (24). Reed and
Maniatis (23) reported that different exon sequences can
affect the efficiency of splice site selection when tested in an
in vitro cis-competition assay. Also, examples of mutations
affecting splicing at a distance are the skipping of exon 5 in
the DHFR gene in Chinese hamster ovary cells (17) or
skipping of exon 2 when transcripts with an altered 5' splice
site in intron 2 of the rabbit ,-globin gene are spliced in vitro
(1). Since alternatively spliced mRNAs are frequently gen-
erated by exon skipping, it seems plausible that this impor-
tant process is controlled by sequences distant from a given
intron, possibly via the interaction of a specific trans-acting
factor (for a review of alternative splicing, see reference 15).
All these results suggest that splicing of an unaltered intron
can be affected by sequence elements around it.
Our previous observations (7) suggest that exon sequences
immediately downstream from an intron can affect the
removal of the intron during splicing. Therefore, we inves-
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tigated whether changing the length of a downstream exon is
sufficient to reduce the efficiency of splicing or whether there
are certain sequence elements necessary for splicing that are
being inadvertently deleted from truncated transcripts. We
also considered that the efficiency of splicing may depend on
the length of the exon upstream from the intron and on
interactions that are needed between the two exons.
To address these questions, we have constructed clones
that contain various sequences, 14 nucleotides downstream
from the 3' splice site, that replace most of exon 2 of the
human P-globin gene. Additional clones were constructed
that contain deletions in exon 1. These clones were trun-
cated at various restriction endonuclease sites and used as
templates to produce pre-mRNA that could be tested for
splicing in an in vitro splicing assay. We found that all of the
sequences used had no effect on splicing efficiency except
substituted sequences from the 5' end of the large intron of
the human or rabbit 3-globin gene. The presence of these
substituted intron sequences in exon 2 inhibits all the steps in
splicing, suggesting that certain regions of the intron may act
as a "poison". sequence under certain conditions. We also
found that the minimum length requirement seen in exon 2 is
independent of the sequence substituted in this region of the
transcript. The same requirement for a minimum length was
not found for exon 1 because transcripts with only 21
nucleotides of exon 1 remaining were spliced as efficiently as
those with the entire exon 1 sequence.
MATERIALS AND METHODS
Plasmid construction. All plasmid constructs were made
from pSP64HBA6 (12). The ends of some restriction frag-
ments were filled in as indicated with DNA polymerase,
Klenow fragment, under the conditions recommended by the
manufacturer (New England Biolabs). pNS constructs were
made by ligating a HaeIII digest of pBR322 to a blunt-ended
AccI digest of pSP64HBA6. p96PL was made by recircula-
rizing a partial AccI digest of pSP64HBA&6, and pPL was
made by recircularizing a blunt-ended complete AccI digest
of pSP64HBA6. pNcol was constructed by digesting
pSP64HBA6 with HindIII and EcoRI, blunt-ending the two
sites, and recircularizing the vector fragment. pHaeIII was
made by ligating the HaeIII restriction fragment that begins
in exon 1 and ends in exon 2 of ,-globin to the HindIII-
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FIG. 1. Effects of nonglobin sequences in exon 2 on the efficiency of in vitro splicing. (A) Splicing of transcripts from the templates pNS64,
pNS124, and pNS184. Transcripts (see panel D for structure) were spliced in a nuclear extract, and products were separated on a 5%
polyacrylamide sequencing gel (see Materials and Methods). The name of each runoff transcript, shown at the top of the lane, includes the
restriction site used to create that transcript as seen in panel D. Lane numbers are shown at the bottom. The structures of the input,
intermediates, and products of splicing of the control (HBA6BamHI, lane 1) are given on the left, and the sizes and positions of the
corresponding bands are given on the right. (The * indicates aberrant mobility due to lariat structures.) Lanes 2 through 4 show splicing of
the NS124, NS184, and NS64 truncated transcripts, respectively. Lane 5 shows splicing of the HBA6AccI truncated transcript, which is not
efficiently spliced but undergoes cleavage at the 5' splice site and lariat formation (7). The presence or absence of the 130* released lariat
splicing product in each lane is a good indicator for efficient splicing since the size or structure of this product is not altered in any of the
constructed templates. (B) Splicing of the PLPstI transcript. Transcript from pPLPstI was spliced in vitro and analyzed in lane 2 as for panel
A. The HBA6BamHI and HBA6AccI controls are in lanes 1 and 3, respectively. (C) Splicing of the %PLBamHI transcript. Transcript from
p96PLBamHI was spliced in vitro and analyzed in lane 2 as for panel A. The HBA6BamHI and HBA6AccI controls are in lanes 1 and 3,
respectively, with the positions and sizes of the HBA6BamHI input, intermediates, and products of splicing to the left. (D) Structure of the
templates. The structures of the templates used to generate the transcripts in panels A, B, and C are shown with the names to the left. The
open boxes are exons, the lightly hatched boxes are polylinker sequence, and the thick hatched boxes are substituted sequences. Thick lines
represent introns, and thin lines represent flanking, nonglobin sequences. A, AccI; B, BamHI; P, PstI; R, EcoRI. Restriction sites destroyed
during cloning are shown in parentheses.
BamHI vector fragment (both ends blunt ended) from pSP64
HBA6. p886HBi2 and p466RBi2 were made by ligating the
AvaII-EcoRI fragment (AvaIl site blunt ended) from intron 2
of the human P-globin gene (pSP64HBA6) or the HincII-
EcoRI fragment from intron 2 of the rabbit P-globin gene
(pRB1+2, a gift from Michael Green, Harvard University),
respectively, to the AccI-EcoRI vector fragment (AccI site
blunt ended) from pSP64HBA6.
Transcription and in vitro splicing. Labeled transcripts
were made from templates linearized with various restriction
enzymes, using the SP6 system and [32P]GTP as previously
described (12). Transcripts were capped in the transcription
reaction (11) and spliced in a 25-pul reaction for various times
as described (12). The products of the reaction were sepa-
rated on a 5% polyacrylamide sequencing gel (6) unless
otherwise indicated.
Quantitation of the efficiency of in vitro splicing. Tran-
scripts were spliced in the standard reactions (see above) in
a time course (tested at 15 min and 30 to 100 min at 10-min
intervals), and the products of the reaction were separated
on a 5% polyacrylamide sequencing gel. The bands corre-
sponding to the input, the intermediates, and products of
splicing were excised, and their radioactivity was deter-
mined by Cerenkov counting. The percent splicing for each
time point was determined by dividing the amount of input
RNA spliced by the total RNA remaining. The amount of
spliced input RNA was calculated by measuring the radio-
activity (counts per minute) in the released lariat intron band
and multiplying it by the ratio of the number ofG nucleotides
in the total transcript versus the number of G nucleotides in
the intron. The released lariat intron was used as a measure
of the amount of spliced input RNA instead of the ligated
exons because it is the only product that remained unaltered
in terms of size and structure in all the transcripts tested.
The total RNA remaining was calculated by adding the
radioactivity in counts per minute in all the bands remaining.
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The percent splicing was normalized for degradation using
the 15-min time point as zero percent splicing. Although the
endogenous nucleases could interfere with the calculations
by degrading the final products, the amount of remaining
RNA after the initial 15-min time point remained constant
throughout the reaction, apparently due to the formation of
the splicing complex (21). Therefore, the percent splicing
calculated for each time point does not appear to be affected
by endogenous nucleases in the extract. The values were
plotted as a function of time versus percent splicing. The
equation for the best line through the points was determined
using linear regression, and the percent splicing at 50 min
(the linear region of the curve) was calculated. For each
transcript, this value was used to construct the curves shown
in Fig. 3 and 5. Thus each point on the curve is calculated
based on the data from at least seven experimental points
(lanes from the gel).
RESULTS
Humanj8-globin gene constructs. We have made a series of
constructs which replace exon 2 sequences after the 14
nucleotides downstream from the 3' splice site with various
sequences to see how substitutions in exon 2 affect splicing.
The structure of these constructs is shown in Fig. 1D and
5D. They include three different HaeIII fragments from
pBR322 (pNS64, pNS124, and pNS184), the polylinker se-
quence from pSP64 (pPL), a sequence normally found in the
3'-flanking region of the P-globin gene (p96PL), and a region
from the large intron of the human (p886HBi2) or rabbit
(p466RBi2) P-globin gene. An additional construct (pRR102,
a gift from Robin Reed and Tom Maniatis, Harvard Univer-
sity, Cambridge, Mass.), similar in structure to p886HBi2,
which contains a portion of the 5' region of the large intron
from the human P-globin gene was also tested. pRR102 and
p886HBi2 are somewhat different in that the inserted intron
2 sequence inpRR102 is missing the first 3 nucleotides of the
intron and the inserted intron 2 sequence in p886HBi2 is
missing the first 11 nucleotides of the intron (see below).
Effects of sequence substitutions in exon 2 on splicing. The
splicing of pre-mRNAs with sequence substitutions in exon
2 is shown in Fig. 1A, B, and C. As a positive control,
splicing of the,-globin pre-mRNA truncated at the BamHI
site is shown with the intermediates and products of the
reaction depicted on the left (lane 1 in Fig. 1A, B, and C). As
a negative control, processing of the P-globin pre-mRNA
truncated at the AccI site, 14 nucleotides downstream from
the 3' splice site, is also shown (Fig. 1A, lane 5; B, lane 3; C,
lane 3). This transcript generates exon 1 and the remaining 3'
half of the molecule in the lariat form, which comigrate in
this gel system, but does not give a band corresponding to
the spliced product or the released lariat intron (7). In all the
lanes containing pre-mRNA with substitutions in exon 2, the
presence of the released lariat intron can be seen (band
130*), indicating that the transcripts are spliced. The identity
of the lariat intron has been determined by its aberrant
mobility on a two-dimensional gel and by its change in
mobility after treatment with debranching activity (25),
present in the cytoplasmic S100 fraction (data not shown).
We use this released lariat intron as an indicator for splicing
since it is the one splicing product that does not change in
size or structure in any of the constructed transcripts.
Additional bands that correspond to the spliced products and
intermediates as determined by their mobility on the gel can
also be seen in each lane, as well as breakdown products
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FIG. 2. Quantitative analysis of the efficiency of splicing of
transcripts with altered exon 2 sequences. The transcripts with
altered exon 2 sequences were spliced in a time-course reaction, and
the products and intermediates were separated on a 5% polyacryl-
amide sequencing gel. The bands were excised, their Cerenkov
radiation was determined, and the efficiency of splicing at 50 min
was calculated (see Materials and Methods) and plotted as a
function of the length of the second exon. Symbols for transcripts:
El, HBA6; +, NS124;O, NS184;*, NS64; *, PL; x,96PL.
tract. The efficiency of splicing of the transcripts shown
above seems to be slightly different in some cases (compare,
for example, the amounts of the released lariat in lane 1 and
4 in Fig. 1A). To determine whether these differences are
real or due to experimental error, we carried out a quantita-
tive analysis for each of the transcripts (see below). How-
ever, we conclude from these results that three different
pBR322 sequences (Fig. 1A, lanes 2 through 4), the poly-
linker sequence from pSP64 (Fig. 1B, lane 2), and a region of
the human ,-globin 3'-flanking sequence (Fig. 1C, lane 2)
can all replace exon 2, 14 nucleotides downstream from the
3' splice site, and restore splicing.
Effects of the length of exon 2 on the efficiency of splicing.
To determine the efficiency of splicing of the transcripts with
exon 2 substitutions, templates were generated by lineariz-
ing the constructs with different restriction endonucleases.
The transcripts generated from these templates were spliced
in a time-course reaction, and the efficiency of splicing was
calculated as described in detail in Materials and Methods.
The results (Fig. 2) were plotted as a function of the percent
splicing at a 50-min time point versus the length of exon 2.
Included in this experiment were RNAs with various lengths
of unmodified P-globin exon 2 transcribed from the pSP64
HBA6 template (HBA6). The efficiency of splicing of HBA6
increased as the length of exon 2 increased, up to 100
nucleotides where it began to plateau. In spite of the small
scattering of the points, this general pattern was seen for all
the truncated transcripts, regardless of the sequence present
in exon 2. For example, transcript HBA6 truncated at the
Sau3A1 site and transcript PL truncated at the EcoRI site
each have a 53- and 47-nucleotide-long exon 2, respectively,
after the 3' splice site. Both of these transcripts spliced at
approximately the same efficiency (15% at 50 min in the
splicing reaction) even though their exon 2 sequences are
different after the initial 14 nucleotides. These results again
show that it is not the specific sequence of the second exon
but the length of the exon that is important for splicing.
Effect of changes in the length of exon 1 on splicing
efficiency. Constructs were made with 50-nucleotide (p5'
NcoI) and 133-nucleotide (p5'HaeIII) deletions in exon 1 of
the human P-globin gene (Fig. 3, bottom) to determine
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FIG. 3. Effects of deletions in exon 1 on the efficiency of
splicing. The transcripts (from the templates diagrammed at the
bottom) were spliced and analyzed as for Fig. 1. The 21-nucleotide
band shown in the center of the figure was resolved on a 20%
polyacrylamide sequencing gel. The sizes (in nucleotides) on the
right refer to the positions and sizes of the HBA6BamHI input,
intermediates, and products of splicing as diagrammed on the left
(see Fig. 1) as well as the 104- and 21-nucleotide exon 1 intermedi-
ates from p5'NcoI and p5'HaeIII, respectively. Names of the
transcripts, including restriction enzymes used for template trunca-
tion, are shown at the top of each lane. N, NcoI; H, HaeIII; other
symbols are described in the legend of Fig. 1. p5'HaeIII has a partial
deletion of exon 2 as a result of cloning.
whether transcripts with exon 1 truncations were able to
splice efficiently. RNAs transcribed from these templates
were spliced as judged by the release of the free lariat intron
(Fig. 3, lanes 2 and 3, band 130*). Additional bands in these
lanes displayed mobilities expected for the other intermedi-
ates and products of splicing, e.g., the 21- and 104-nucleotide
released exon 1 splicing intermediates for p5'HaeIII and
p5'NcoI, respectively. Small amounts of the released lariat
intron were also detected when p5'NcoI and p5'HaeIII
RNAs that extended to the AccI site in exon 2 were spliced
in vitro (Fig. 3, lanes 5 and 6). Since ,B-globin transcripts with
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FIG. 4. Quantitative analysis of the efficiency of splicing of
transcripts with deletions in exon 1. The efficiency of splicing of
transcripts shown in Fig. 3 was quantitated and plotted as for Fig. 2.
The solid line shows the efficiency of splicing of the transcripts from
pSP64HBA6 with the full-length exon 1. Symbols for templates: El,
SP64HBA6; x, NcoI; +, HaeIII.
were not efficiently spliced (Fig. 3, lane 4; see also Fig. 1A,
lane 5, Fig. 1B and C, lane 3, and reference 7), the splicing
of these transcripts was unexpected. However, although the
spliced products from these exon 1 deletion transcripts could
be seen, splicing was still very inefficient (see quantitations
in Fig. 4 below).
Effects of exon 1 deletions on the efficiency of splicing with
different exon 2 truncations. The efficiency of splicing of
transcripts containing exon 1 deletions with different
amounts of exon 2 was quantitated and plotted in the same
manner as described for Fig. 2. The results are shown (Fig.
4) superimposed on the curve of the splicing efficiency of the
HBA6 transcripts containing the full-length exon 1 with
different amounts of exon 2. Although small deviations from
the curve can be seen, the efficiency of splicing of the exon
1 deletion transcripts followed the same general pattern
found for the HBA6 truncated transcripts. Therefore, we
conclude that deletions in exon 1 do not affect the efficiency
of splicing or significantly alter the requirement for a mini-
mum exon 2 length seen for transcripts truncated at various
positions in exon 2. In addition, the overall size of the
transcript, within the limits tested, does not appear to be
important for splicing. A transcript with a shortened exon 1
and a full-length exon 2 spliced with a much higher efficiency
than a transcript with a full-length exon 1 and a truncated
exon 2, even though both transcripts were the same size (see
Fig. 3, lane 3 versus lane 4, respectively; see quantitation in
Fig. 4).
Inhibition of splicing by substituting fragments from the
large 3-globin intron 2 for exon 2 sequences. The results
presented above establish that transcripts with truncated
exon 2 sequences are not efficiently spliced but that splicing
can be restored if a certain length of exon 2 is reconstructed
with nonglobin fragments, regardless of the sequence. Sur-
prisingly, we have encountered a few substituted fragments
that will not rescue splicing, one of which is a Hinfl-DraI
fragment from the large intron (IVS2) of the human 3-globin
gene termed plasmid pRR102. When the transcript from the
pRR102 template, truncated at an RsaI site (leaving 100
nucleotides of IVS2 sequence), was spliced in vitro, none of
the intermediates or products were generated (Fig. 5A, lane
3). The same result was obtained when a transcript carrying
500 nucleotides of IVS2 was generated from the pRR102
template (data not shown). These results are different from
those obtained with the HBA6 transcript truncated at the
AccI site, which did not efficiently generate the final splicing
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FIG. 5. Analysis of the splicing of transcripts with intron sequences substituted for exon 2. (A) Splicing of transcripts from the template
pRR102. Transcript was spliced in a nuclear extract and analyzed as described for Fig. 1. (See Fig. 5D and the labels at the top of each lane
for the structure and a description of each transcript, respectively.) The structures on the left and the sizes on the right for the control
HBA6BamHI (lane 1) input, intermediates, and products of splicing are the same as for Fig. 1A. Splicing of the HBA6AccI transcript is in
lane 4 (see Fig. 1A). (B) Splicing of the HBi2RsaI transcript. Transcript from p886HBi2 was spliced in vitro and analyzed in lane 2 as for panel
A. The HBA6BamHI and HBA6AccI controls are in lanes 1 and 3, respectively. (C) Splicing of the RBi2ScaI transcript. Transcript from
p466RBi2 was spliced in vitro and analyzed in lane 2 as for panel A. The HBA&6BamHI and HBA6AccI controls are in lanes 1 and 3,
respectively, with the positions and sizes of the HBA6BamHI input, intermediates, and products of splicing to the left. (D) Structure of the
templates. The structures of the templates used to generate the transcripts in panels A, B, and C are shown with the names to the left. Av,
AvaIl; Rs, RsaI; Sc, ScaI; other symbols and restriction sites are described in the legend of Fig. 1. (E) Nucleotide sequence of the poison
sequence found in p886HBi2 and p446RBi2. A portion of the nucleotide sequence from a fragment of intron 2 of the human (GenBank entry
HUMHBB, nucleotides 723 to 784) and rabbit (GenBank entry RABHBBlA1, nucleotides 1085 to 1148) P-globin genes, used to construct
p886HBi2 and p466RBi2, respectively, is shown. The positions of the Avall and the HincIl sites used to construct the clones (see Materials
and Methods for the construction protocol) are indicated by an arrow. The pyrimidines found in this sequence are indicated with a dot.
products but accumulated the intermediates of splicing (Fig.
SA, lane 4). In contrast, when pRR102 was truncated 30
nucleotides after the 3' splice site (with 15 nucleotides of
intron 2 sequences remaining), the transcript was efficiently
spliced and the intermediates and products were generated
at the same rate as those of other transcripts having a similar
length sequence after the 3' splice site (Fig. 5A, lane 2;
quantitation not shown). These results suggest that the
sequence element involved in the splicing inhibition in
pRR102 is contained in a region of intron 2 between the
AvaII-RsaI sites (Fig. 5D). To show that the first 15 nucle-
otides of the inserted sequence are not involved (a possibility
stemming from the fact that this sequence has a portion of
the proposed U1-RNP binding site from intron 2 remaining
[18, 19]), we constructed a clone, p886HBi2, by placing an
intron 2 fragment that begins at the Avall site after the first
14 nucleotides of exon 2. Again, transcripts truncated at the
RsaI site were not efficiently spliced in vitro (although a
small amount of cleavage occurred at the 5' splice site; Fig.
SB, lane 2), identifying the inhibiting sequence within the 70
nucleotides of the AvaII-RsaI region. We also constructed a
clone with a structure similar to that of p886HBi2 by
substituting a portion of the rabbit P-globin intron 2 at a point
14 nucleotides from the 3' splice site (p466RBi2). A tran-
script with 117 nucleotides of intron 2 (RBi2ScaI) was not
spliced in vitro (Fig. 5C, lane 2). To ascertain that these
results were not due to slower kinetics of splicing, we
performed time-course experiments for the RR102RsaI,
HBi2RsaI, and RBi2ScaI truncated transcripts. No signifi-
cant accumulation of splicing products could be detected for
any of the transcript after 120 min of incubation, although a
small amount of 5' splice site cleavage products could be
seen for HBi2RsaI (data not shown).
A comparison of the poison sequence from the human
versus the rabbit intron 2 is shown in Fig. SE. The most
striking similarity between these sequences is that they have
long stretches of pyrimidines (20 long in the human intron
and 26 long with only two purines in the rabbit intron).
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A possible mechanism for the inhibition of splicing by the
poison sequence is that it competes better for binding to
certain splicing factors than the normal binding sites in the
pre-mRNA. To test this possibility, we carried out splicing
of HBA6 transcripts truncated at either the BamHI or AccI
site in the presence of a 2.5-fold excess of transcript
HBi2RsaI. We did not attempt competitions with higher
concentrations of the transcript containing the poison se-
quence because we have found that high concentrations of
the substrate alone inhibit the splicing reaction. Under these
conditions HBiRsaI had no effect on the efficiency of splicing
of HBA6 transcripts, suggesting that the poison sequence
cannot act in trans and is not depleting the extract of an
essential splicing factor (data not shown).
DISCUSSION
We have previously shown (7; see also reference 24) that
a transcript from the human 3-globin gene, with only 14
nucleotides of exon 2 sequence at the 3' end, does not
efficiently undergo the final step in splicing, i.e., cleavage at
the 3' splice site and exon ligation. The transcript is cleaved
at the 5' splice site, accumulating the exon 1 and the intron
1-exon 2 lariat intermediates. The inefficient splicing of this
transcript suggested that either there is a minimum size
requirement of the second exon for splicing, or an important
sequence found in this exon has been deleted in the trun-
cated transcript. The likelihood of this latter possibility was
raised by the results of Reed and Maniatis (23), who showed
that exon sequences affect the efficiency of splice site
selection in a cis-competition assay. The results shown here
suggest that the inability of this transcript to generate spliced
products is due to the lack of a minimum size for the second
exon. We also show that splicing can be restored with a
variety of non-3-globin-related sequences substituted for
exon 2 and that these sequences do not affect the exon 2
minimum size requirement. In contrast to truncations in
exon 2, deletions in exon 1, the largest of which reduces the
size of exon 1 to 21 nucleotides, have no major effect on
splicing in this system. Although a very small increase in the
splicing efficiency of transcripts with exon 1 deletions trun-
cated at the AccI site was observed (Fig. 4), it does not seem
to change the general pattern of the minimum size require-
ment for exon 2. All of the above results were quantitated by
time-course experiments and show that the inability of
certain transcripts to splice is not due to slower kinetics in
the in vitro reaction. Since, within the limits tested, the
overall size of the transcript is unrelated to the efficiency of
splicing, it appears instead that an important requirement for
efficient splicing is that an intron be present no less than 15
nucleotides upstream from the 3' end of the pre-mRNA.
We presume that the reason for this size requirement is the
physical need for a certain length of an exon to act as an
anchor for splicing factors that are positioned at the 3' splice
site. This is supported by a study that used the Miller
chromatin spreading technique to identify 25-nm particles
that bind to intron-exon junctions and cover a total of
approximately 150 bases ofRNA (20). Therefore, we reason
that transcripts with less than 50 nucleotides (see Fig. 2) of
exon 2 are not spliced well because they are unable to bind
efficiently to certain factors in the splicing complex. Tran-
scripts generated with our clones have been examined by P.
Goswami and C. Goldenberg (personal communication) for
UV cross-linking to proteins present in the splicing complex.
As a general pattern, Goswami and Goldenberg found that
heterogeneous nuclear RNP core proteins, which have been
shown to be essential for splicing (5, 28), bound to these
transcripts in increased amounts as the length of exon 2 in
these transcripts (and the efficiency of splicing) increased.
Since Bindereif and Green (2a) showed that truncation of the
second exon does not affect binding of small nuclear RNPs,
it appears that the interaction of heterogeneous nuclear RNP
core proteins with exon sequences may contribute to the
efficiency of splicing.
Another important consideration is whether a minimum
exon size requirement could be involved in splicing in vivo
since short exons, shorter than 50 nucleotides, do occur in
pre-mRNA (for example, the third exon of the troponin I
gene is only 7 nucleotides long; see reference 2). For the
splicing of a multi-intron pre-mRNA, the results above
would first argue that an intron with a short downstream
exon cannot be spliced out unless the short exon is first
joined to the exon further downstream. This would effec-
tively increase the size of the exon and remove any inhibi-
tory sequences that may be found in the adjacent intron.
Thus, it seems plausible that this mechanlsn could describe
a method of ordering the removal of introns.
We have shown by quantitating the efficiency of splicing
that most but not all sequences can substitute for exon 2 and
allow splicing in the human 0-globin gene. The advantages of
this procedure are that it uses the standard assay, can be
applied to any transcript, and corrects for differences in the
initial degradation of the input pre-mRNA seen in different
experiments. With this method it is possible not only to
identify transcripts which can or cannot splice, but also to
observe which transcripts splice at efficiencies somewhere in
between these extremes. It is unlikely that this method can
be used to differentiate the relative strength of particular
sequences that show similar efficiencies of in vitro splicing.
For these results, a competition assay, such a the one used
by Kuhne et al. (13), Lang and Spritz (14), and Reed and
Maniatis (23), is more useful for seeing these small differ-
ences.
One striking result that we observed is the identification of
two sequences, one in the 5' region of the large intron of the
human ,3-globin gene and the other located in approximately
the same region of the rabbit 3-globin gene, that act as
poison sequences when inserted close to the 3' splice site in
the downstream exon. As shown above, these sequences
completely inhibit splicing when positioned 14 and 31 nucle-
otides downstream from the 3' splice site (transcripts
HBi2RsaI or RBi2ScaI and transcript RR102RsaI, respec-
tively). To see whether the poison sequence could inhibit
splicing when positioned further away from the 3' splice site,
we generated a transcript from the pSP64HBA6 template
truncated at the RsaI site in IVS2. In this transcript, the
poison sequence begins 236 nucleotides downstream from
the 3' splice site of IVS1 (11 nucleotides from the 5' splice
site of IVS2). The efficiency of splicing for this transcript
appeared to be lower than the efficiency seen with the
BamHI-truncated transcript (data not shown). Since the
effect was small, it is not clear whether this sequence affects
the efficiency of splicing at a distance.
We do not yet know how the poison sequences can inhibit
splicing in vitro, since they are found normally in IVS2 of
both human and rabbit 3-globin and do not appear to inhibit
splicing in vivo. Moreover, the poison sequence can be
deleted from the rabbit IVS2 without affecting splicing in
vivo (30). The poison sequence may be inhibiting splicing in
our constructs by altering the binding of specific factors or
affecting the secondary structure of the pre-mRNA. We have
looked at computer-generated secondary structures (10) of
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the poison sequences alone and in a series of transcripts and
can see no common significant features that might suggest
that the poison sequence may be blocking essential regions
of the molecule by base pairing. Therefore it seems more
likely that this sequence interacts with factors in the splicing
extract and inhibits formation of the active splicing complex.
These factors could be the same ones involved in binding at
the 3' splice site near the polypyrimidine stretch and the
branch point (3, 4, 8, 26, 29) or a new series of factors that
have not yet been identified. Alternatively, the poison se-
quence may prevent essential factors from binding to the
transcript. This idea is supported by the observation of
Goswami and Goldenberg that, in contrast to normal ,-
globin pre-mRNA (HBA6BamHI), transcript HBi2RsaI was
not able to cross-link any of the heterogeneous nuclear RNP
proteins in the splicing extract (personal communication). In
addition, preliminary results suggest that transcripts with
poison sequence form complexes that sediment slower than
active spliceosomes through glycerol gradients (R. Kole,
unpublished data). Understanding how these sequences are
inhibiting splicing will determine whether they play a role in
splicing in viVO.
After this work was completed, Parent et al. (22) reported
similar results regarding exon requirements in in vitro splic-
ing.
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